Angiopoietin-2 levels as a biomarker of cardiovascular risk in patients with hypertension

Research output: Contribution to journalArticle

Authors

Colleges, School and Institutes

Abstract

BACKGROUND: Abnormal angiogenesis is a pathophysiological component of cardiovascular disease (CVD), where circulating biomarkers of angiogenesis are associated with increased CVD risk in hypertension. We hypothesized that raised levels of angiopoietin (Ang)-1 and -2 would predict events in patients with hypertension treated for CVD. METHODS: We measured angiopoietin levels by enzyme-linked immunosorbent assay (ELISA) in 251 hypertensive participants (85% male; mean age 63.5 years; 192 free of previous CVD events). Plasma angiopoietin levels were related to the subsequent CVD events over a mean follow-up period of 57.1 (SD 11) months. RESULTS: There were 11 cases of myocardial infarction (MI) and 18 cases of stroke during follow-up. Ang-2 was a significant predictor of MI, stroke, and composite CVD events, with the greatest event-free survival amongst those in the lower tertile (all P4.3 ng/mL optimized specificity and sensitivity. On Cox regression analysis (CVD treatments and risk factors), raised Ang-2 was an independent predictor of MI, P

Details

Original languageEnglish
Pages (from-to)215-22
Number of pages8
JournalInternational Journal of Clinical Practice
Volume40
Issue number3
Publication statusPublished - 1 Jan 2008